Related Experiment Video
Updated: Jan 31, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for
Nisha R Bhat1, Joel M Vetter1, Gerald L Andriole1
1Division of Urology, Washington University School of Medicine, St. Louis, MO; Department of Radiology, Washington University School of Medicine, St. Louis, MO.
Objective:
To evaluate the predictive value of magnetic resonance imaging (MRI)-defined prostate-specific antigen (PSA) density and MRI interpretation for the detection of clinically significant prostate cancer (PCa).
Methods:
We retrospectively reviewed our institutional database of men who received prostate MRI prior to biopsy at our institution between September 2014 and December 2016, excluding those on active surveillance (n = 372). Logistic regression models to predict clinically significant PCa on biopsy were developed using (1) MRI-defined PSA density; (2) PSA alone; and (3) the Prostate Cancer Prevention Trial (PCPT) risk calculator. Additional logistic regression models were then generated by combining the previous clinical variables with MRI interpretation (ie, prostate imaging reporting and data system [PI-RADS] classification): (1) MRI-defined PSA density + MRI interpretation; (2) PSA + MRI interpretation; and (3) PCPT + MRI interpretation. Receiving operator characteristic curves for each of the 6 models were generated, and the area under the curves (AUC) were compared.
Results:
MRI-defined PSA density (AUCPSAD = 0.77) significantly outperformed the PSA (AUCPSA = 0.66, P < .01) and PCPT models (AUCPCPT = 0.70, P < .01). When combined with MRI interpretation (ie, PI-RADS classification), the MRI-defined PSA density model (AUCPSAD + MRI = 0.80) significantly outperformed the PSA (AUCPSA + MRI = 0.75, P < .01) and PCPT models (AUCPCPT + MRI = 0.76, P = .01).
Conclusion:
In addition to the PI-RADS classification, prebiopsy multiparametric magnetic resonance imaging also provides an accurate assessment of prostate volume. By utilizing this additional data to determine MRI-defined PSA density, we find that risk discrimination for clinically significant PCa on biopsy can be significantly improved.
Insights
Magnetic resonance imaging (MRI)-defined prostate-specific antigen (PSA) density improves prostate cancer detection. Combining MRI-defined PSA density with MRI interpretation (PI-RADS) further enhances risk assessment for clinically significant prostate cancer.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Prostate cancer (PCa) detection relies on various diagnostic tools.
- Accurate risk stratification is crucial for effective PCa management.
- Multiparametric magnetic resonance imaging (mpMRI) is increasingly used in PCa diagnostics.
Purpose of the Study:
- To assess the predictive accuracy of MRI-defined PSA density and MRI interpretation for detecting clinically significant PCa.
- To compare the performance of models incorporating MRI data with traditional methods like PSA levels and risk calculators.
Main Methods:
- Retrospective analysis of 372 men undergoing pre-biopsy prostate MRI.
- Development of logistic regression models using PSA density, PSA alone, and the PCPT risk calculator.
- Generation of combined models integrating MRI interpretation (PI-RADS) with clinical variables.
- Comparison of model performance using receiver operating characteristic curves and area under the curve (AUC) analysis.
Main Results:
- MRI-defined PSA density (AUC=0.77) significantly outperformed PSA (AUC=0.66) and PCPT models (AUC=0.70).
- Combining MRI-defined PSA density with PI-RADS classification (AUC=0.80) significantly improved prediction compared to PSA + PI-RADS (AUC=0.75) and PCPT + PI-RADS (AUC=0.76).
Conclusions:
- MRI-defined PSA density offers superior risk discrimination for clinically significant PCa compared to PSA alone or the PCPT calculator.
- Integrating prostate volume assessment from MRI to calculate PSA density significantly enhances diagnostic accuracy.
- The combination of MRI-defined PSA density and PI-RADS classification provides robust risk assessment for PCa detection.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies IV: Magnetic Resonance Imaging
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Atomic Nuclei: Magnetic Resonance
Density, Specific Weight, Specific Gravity and Compressibility of Fluid
Specific weight represents the weight per unit volume and is calculated by multiplying...
Nuclear Magnetic Resonance (NMR): Overview
NMR spectroscopy generates a spectrum where the characteristic absorption frequencies of the sample are...

